Association between nuclear expression of retinoic acid receptor alpha and beta and clinicopathological features and prognosis of advanced non-small cell ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2016-06-15

AUTHORS

Saé Muñiz-Hernández, Sara Huerta-Yepez, Norma Hernández-Pedro, Laura-Alejandra Ramírez-Tirado, Alejandro Aviles-Salas, Altagracia Maldonado, Daniel Hernández-Cueto, Guillermina Baay-Guzmán, Oscar Arrieta

ABSTRACT

BackgroundTranscription factors such as retinoic acid receptor alpha (RARα) and beta (RARβ) and Yin Yang 1 (YY1) are associated with the progression of non-small cell lung cancer (NSCLC). In particular, a lack of RARβ expression is associated with NSCLC development. The aim of this study was to analyze the expression of RARα, RARβ and YY1 and their relationship with prognosis in patients with advanced NSCLC.MethodsThe expression of RARα, RARβ and YY1 was assessed by immunohistochemistry and quantitative computerized image software.ResultsEighty-five patients treated with platinum-based chemotherapy were included in the analysis. The mean and standard deviation of the nuclear expression of RARα, RARβ and YY1 were 184.5 ± 124.4, 18 ± 27 and 16.6 ± 20.5, respectively. The nuclear expression of RARβ was associated with the nuclear expression of YY1 (R2 = 0.28; p value < 0.0001). Patients with high nuclear expression of YY1 were likely to be non-smokers (61.9 vs 40.5 %). Median progression-free survival (PFS) was 5.9 months (3.48–8.28). Low expression of RARα was independently associated with worse PFS following chemotherapy (10.3 vs 5.46 months p = 0.040). Median overall survival (OS) was 15.6 months (4.5–26.7), and lower nuclear expression of RARβ was independently associated with shorter OS (27.5 vs 8.7 months; p = 0.037).ConclusionOur study suggests that the loss of RARs is associated with a worse prognosis and these receptors could be a potential molecular target for NSCLC. More... »

PAGES

1051-1061

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10147-016-1002-0

DOI

http://dx.doi.org/10.1007/s10147-016-1002-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1048664941

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/27306217


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Non-Small-Cell Lung", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cisplatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diagnosis, Computer-Assisted", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gene Expression Regulation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunohistochemistry", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lung Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Retinoic Acid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retinoic Acid Receptor alpha", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Transcription Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "YY1 Transcription Factor", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Laboratory of Personalized Medicine, Instituto Nacional de Cancerolog\u00eda, Mexico City, Mexico", 
          "id": "http://www.grid.ac/institutes/grid.419167.c", 
          "name": [
            "Laboratory of Personalized Medicine, Instituto Nacional de Cancerolog\u00eda, Mexico City, Mexico"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mu\u00f1iz-Hern\u00e1ndez", 
        "givenName": "Sa\u00e9", 
        "id": "sg:person.01335727426.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01335727426.76"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Molecular Markers Laboratory, Hospital Infantil de M\u00e9xico \u201cFederico G\u00f3mez\u201d, Secretar\u00eda de Salud, Mexico City, Mexico", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Molecular Markers Laboratory, Hospital Infantil de M\u00e9xico \u201cFederico G\u00f3mez\u201d, Secretar\u00eda de Salud, Mexico City, Mexico"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Huerta-Yepez", 
        "givenName": "Sara", 
        "id": "sg:person.01171343223.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171343223.95"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Laboratory of Personalized Medicine, Instituto Nacional de Cancerolog\u00eda, Mexico City, Mexico", 
          "id": "http://www.grid.ac/institutes/grid.419167.c", 
          "name": [
            "Laboratory of Personalized Medicine, Instituto Nacional de Cancerolog\u00eda, Mexico City, Mexico"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hern\u00e1ndez-Pedro", 
        "givenName": "Norma", 
        "id": "sg:person.01266562033.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01266562033.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Thoracic Oncology Unit, Instituto Nacional de Cancerolog\u00eda, San Fernando # 22, Tlalpan, 14080, Mexico City, Mexico", 
          "id": "http://www.grid.ac/institutes/grid.419167.c", 
          "name": [
            "Thoracic Oncology Unit, Instituto Nacional de Cancerolog\u00eda, San Fernando # 22, Tlalpan, 14080, Mexico City, Mexico"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ram\u00edrez-Tirado", 
        "givenName": "Laura-Alejandra", 
        "id": "sg:person.01173460062.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01173460062.64"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pathology, Instituto Nacional de Cancerolog\u00eda, Mexico City, Mexico", 
          "id": "http://www.grid.ac/institutes/grid.419167.c", 
          "name": [
            "Department of Pathology, Instituto Nacional de Cancerolog\u00eda, Mexico City, Mexico"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Aviles-Salas", 
        "givenName": "Alejandro", 
        "id": "sg:person.01366302515.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01366302515.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Molecular Markers Laboratory, Hospital Infantil de M\u00e9xico \u201cFederico G\u00f3mez\u201d, Secretar\u00eda de Salud, Mexico City, Mexico", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Molecular Markers Laboratory, Hospital Infantil de M\u00e9xico \u201cFederico G\u00f3mez\u201d, Secretar\u00eda de Salud, Mexico City, Mexico"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Maldonado", 
        "givenName": "Altagracia", 
        "id": "sg:person.010010511261.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010010511261.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Molecular Markers Laboratory, Hospital Infantil de M\u00e9xico \u201cFederico G\u00f3mez\u201d, Secretar\u00eda de Salud, Mexico City, Mexico", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Molecular Markers Laboratory, Hospital Infantil de M\u00e9xico \u201cFederico G\u00f3mez\u201d, Secretar\u00eda de Salud, Mexico City, Mexico"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hern\u00e1ndez-Cueto", 
        "givenName": "Daniel", 
        "id": "sg:person.01244323444.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01244323444.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Molecular Markers Laboratory, Hospital Infantil de M\u00e9xico \u201cFederico G\u00f3mez\u201d, Secretar\u00eda de Salud, Mexico City, Mexico", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Molecular Markers Laboratory, Hospital Infantil de M\u00e9xico \u201cFederico G\u00f3mez\u201d, Secretar\u00eda de Salud, Mexico City, Mexico"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Baay-Guzm\u00e1n", 
        "givenName": "Guillermina", 
        "id": "sg:person.01123511101.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01123511101.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Thoracic Oncology Unit, Instituto Nacional de Cancerolog\u00eda, San Fernando # 22, Tlalpan, 14080, Mexico City, Mexico", 
          "id": "http://www.grid.ac/institutes/grid.419167.c", 
          "name": [
            "Laboratory of Personalized Medicine, Instituto Nacional de Cancerolog\u00eda, Mexico City, Mexico", 
            "Thoracic Oncology Unit, Instituto Nacional de Cancerolog\u00eda, San Fernando # 22, Tlalpan, 14080, Mexico City, Mexico"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Arrieta", 
        "givenName": "Oscar", 
        "id": "sg:person.0711063504.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0711063504.30"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2016-06-15", 
    "datePublishedReg": "2016-06-15", 
    "description": "BackgroundTranscription factors such as retinoic acid receptor alpha (RAR\u03b1) and beta (RAR\u03b2) and Yin Yang 1 (YY1) are associated with the progression of non-small cell lung cancer (NSCLC). In particular, a lack of RAR\u03b2 expression is associated with NSCLC development. The aim of this study was to analyze the expression of RAR\u03b1, RAR\u03b2 and YY1 and their relationship with prognosis in patients with advanced NSCLC.MethodsThe expression of RAR\u03b1, RAR\u03b2 and YY1 was assessed by immunohistochemistry and quantitative computerized image software.ResultsEighty-five patients treated with platinum-based chemotherapy were included in the analysis. The mean and standard deviation of the nuclear expression of RAR\u03b1, RAR\u03b2 and YY1 were 184.5\u00a0\u00b1\u00a0124.4, 18\u00a0\u00b1\u00a027 and 16.6\u00a0\u00b1\u00a020.5, respectively. The nuclear expression of RAR\u03b2 was associated with the nuclear expression of YY1 (R2\u00a0=\u00a00.28; p value\u00a0<\u00a00.0001). Patients with high nuclear expression of YY1 were likely to be non-smokers (61.9 vs 40.5\u00a0%). Median progression-free survival (PFS) was 5.9\u00a0months (3.48\u20138.28). Low expression of RAR\u03b1 was independently associated with worse PFS following chemotherapy (10.3 vs 5.46\u00a0months p\u00a0=\u00a00.040). Median overall survival (OS) was 15.6\u00a0months (4.5\u201326.7), and lower nuclear expression of RAR\u03b2 was independently associated with shorter OS (27.5 vs 8.7\u00a0months; p\u00a0=\u00a00.037).ConclusionOur study suggests that the loss of RARs is associated with a worse prognosis and these receptors could be a potential molecular target for NSCLC.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10147-016-1002-0", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1312225", 
        "issn": [
          "1341-9625", 
          "1437-7772"
        ], 
        "name": "International Journal of Clinical Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "21"
      }
    ], 
    "keywords": [
      "non-small cell lung cancer", 
      "progression-free survival", 
      "advanced non-small cell lung cancer", 
      "cell lung cancer", 
      "retinoic acid receptor alpha", 
      "overall survival", 
      "acid receptor alpha", 
      "nuclear expression", 
      "Yin Yang 1", 
      "lung cancer", 
      "receptor alpha", 
      "median progression-free survival", 
      "worse progression-free survival", 
      "loss of RAR", 
      "median overall survival", 
      "platinum-based chemotherapy", 
      "expression of RAR\u03b1", 
      "shorter overall survival", 
      "low nuclear expression", 
      "high nuclear expression", 
      "potential molecular targets", 
      "RAR\u03b2 expression", 
      "worse prognosis", 
      "clinicopathological features", 
      "NSCLC development", 
      "MethodsThe expression", 
      "ConclusionOur study", 
      "low expression", 
      "patients", 
      "prognosis", 
      "RAR\u03b1", 
      "molecular targets", 
      "RAR\u03b2", 
      "chemotherapy", 
      "cancer", 
      "months", 
      "Yang 1", 
      "survival", 
      "expression", 
      "alpha", 
      "image software", 
      "beta", 
      "immunohistochemistry", 
      "progression", 
      "receptors", 
      "RAR", 
      "study", 
      "association", 
      "aim", 
      "target", 
      "factors", 
      "lack", 
      "loss", 
      "standard deviation", 
      "development", 
      "relationship", 
      "analysis", 
      "features", 
      "deviation", 
      "software", 
      "BackgroundTranscription factors"
    ], 
    "name": "Association between nuclear expression of retinoic acid receptor alpha and beta and clinicopathological features and prognosis of advanced non-small cell lung cancer", 
    "pagination": "1051-1061", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1048664941"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10147-016-1002-0"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "27306217"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10147-016-1002-0", 
      "https://app.dimensions.ai/details/publication/pub.1048664941"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-20T07:32", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_702.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10147-016-1002-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10147-016-1002-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10147-016-1002-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10147-016-1002-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10147-016-1002-0'


 

This table displays all metadata directly associated to this object as RDF triples.

262 TRIPLES      21 PREDICATES      106 URIs      98 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10147-016-1002-0 schema:about N011e24c6f2784b26a003f6b6e61309c4
2 N0c7fdfeb07864734a05ed3b64942ea9f
3 N368e3816b4e649f2a40a04083a6049d6
4 N69e2654b21574aeeae09465538ae63d7
5 N76dde25a71b04f09bd3cb420d4169077
6 N82a900df8f4f4fdba97800c9d2ef2b4f
7 N94fd1da861bd4243b6d008ae341e85dc
8 N97a92abe4eb2430a85a57414d3f6bbc9
9 N991e5e78a52c4c6baebb53b1d969c040
10 Na6ddb9c31f944492ac6bdbca429057df
11 Nbb7ca465729c42348b32b10cbd8d67b7
12 Nc608bf54d55b4bf6bb0f71aadcff197f
13 Nc6ca3df04c1d40ae987c0712eb1f7b3d
14 Nc8fbb58c583041ef974cd8d3e7f48aad
15 Ncbe13d46008f40349e5e87fa37ceaf8a
16 Ne8d45cbede57484da7c06f46f97821b5
17 Ned80bdf564bd4af9a63ec269b8d9157b
18 Nf63a74bd309548fe8bab401bdff3b6d3
19 Nfcda6e38b69b4a32832875f81d247c69
20 anzsrc-for:11
21 anzsrc-for:1112
22 schema:author N0a74c598aad74d3194bf82576fe6d5ba
23 schema:datePublished 2016-06-15
24 schema:datePublishedReg 2016-06-15
25 schema:description BackgroundTranscription factors such as retinoic acid receptor alpha (RARα) and beta (RARβ) and Yin Yang 1 (YY1) are associated with the progression of non-small cell lung cancer (NSCLC). In particular, a lack of RARβ expression is associated with NSCLC development. The aim of this study was to analyze the expression of RARα, RARβ and YY1 and their relationship with prognosis in patients with advanced NSCLC.MethodsThe expression of RARα, RARβ and YY1 was assessed by immunohistochemistry and quantitative computerized image software.ResultsEighty-five patients treated with platinum-based chemotherapy were included in the analysis. The mean and standard deviation of the nuclear expression of RARα, RARβ and YY1 were 184.5 ± 124.4, 18 ± 27 and 16.6 ± 20.5, respectively. The nuclear expression of RARβ was associated with the nuclear expression of YY1 (R2 = 0.28; p value < 0.0001). Patients with high nuclear expression of YY1 were likely to be non-smokers (61.9 vs 40.5 %). Median progression-free survival (PFS) was 5.9 months (3.48–8.28). Low expression of RARα was independently associated with worse PFS following chemotherapy (10.3 vs 5.46 months p = 0.040). Median overall survival (OS) was 15.6 months (4.5–26.7), and lower nuclear expression of RARβ was independently associated with shorter OS (27.5 vs 8.7 months; p = 0.037).ConclusionOur study suggests that the loss of RARs is associated with a worse prognosis and these receptors could be a potential molecular target for NSCLC.
26 schema:genre article
27 schema:inLanguage en
28 schema:isAccessibleForFree false
29 schema:isPartOf N60a5b4fb9ff44bdc82e5f8a21ed4d9d3
30 Nda08c5885fa84af6a13153f5884d9c4c
31 sg:journal.1312225
32 schema:keywords BackgroundTranscription factors
33 ConclusionOur study
34 MethodsThe expression
35 NSCLC development
36 RAR
37 RARα
38 RARβ
39 RARβ expression
40 Yang 1
41 Yin Yang 1
42 acid receptor alpha
43 advanced non-small cell lung cancer
44 aim
45 alpha
46 analysis
47 association
48 beta
49 cancer
50 cell lung cancer
51 chemotherapy
52 clinicopathological features
53 development
54 deviation
55 expression
56 expression of RARα
57 factors
58 features
59 high nuclear expression
60 image software
61 immunohistochemistry
62 lack
63 loss
64 loss of RAR
65 low expression
66 low nuclear expression
67 lung cancer
68 median overall survival
69 median progression-free survival
70 molecular targets
71 months
72 non-small cell lung cancer
73 nuclear expression
74 overall survival
75 patients
76 platinum-based chemotherapy
77 potential molecular targets
78 prognosis
79 progression
80 progression-free survival
81 receptor alpha
82 receptors
83 relationship
84 retinoic acid receptor alpha
85 shorter overall survival
86 software
87 standard deviation
88 study
89 survival
90 target
91 worse prognosis
92 worse progression-free survival
93 schema:name Association between nuclear expression of retinoic acid receptor alpha and beta and clinicopathological features and prognosis of advanced non-small cell lung cancer
94 schema:pagination 1051-1061
95 schema:productId N1237df71d95449618337539bcbb6510d
96 N3b8963b3fb384ba68e233212e3fc16b0
97 Nc12e95dfd85d46d3a03e375f9477f1cd
98 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048664941
99 https://doi.org/10.1007/s10147-016-1002-0
100 schema:sdDatePublished 2022-05-20T07:32
101 schema:sdLicense https://scigraph.springernature.com/explorer/license/
102 schema:sdPublisher N024666cb0c0f472296b26865d3bbd686
103 schema:url https://doi.org/10.1007/s10147-016-1002-0
104 sgo:license sg:explorer/license/
105 sgo:sdDataset articles
106 rdf:type schema:ScholarlyArticle
107 N011e24c6f2784b26a003f6b6e61309c4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Adult
109 rdf:type schema:DefinedTerm
110 N024666cb0c0f472296b26865d3bbd686 schema:name Springer Nature - SN SciGraph project
111 rdf:type schema:Organization
112 N0a74c598aad74d3194bf82576fe6d5ba rdf:first sg:person.01335727426.76
113 rdf:rest N344e872d4b054a88b88bc03a910c7c78
114 N0c7fdfeb07864734a05ed3b64942ea9f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Male
116 rdf:type schema:DefinedTerm
117 N1237df71d95449618337539bcbb6510d schema:name pubmed_id
118 schema:value 27306217
119 rdf:type schema:PropertyValue
120 N210e6a9d5cbc495a91eb8a7598fb3c46 rdf:first sg:person.01266562033.98
121 rdf:rest N77cfe1633f1a4f3ba0ec4bdf6f150ed1
122 N344e872d4b054a88b88bc03a910c7c78 rdf:first sg:person.01171343223.95
123 rdf:rest N210e6a9d5cbc495a91eb8a7598fb3c46
124 N368e3816b4e649f2a40a04083a6049d6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Humans
126 rdf:type schema:DefinedTerm
127 N3b8963b3fb384ba68e233212e3fc16b0 schema:name dimensions_id
128 schema:value pub.1048664941
129 rdf:type schema:PropertyValue
130 N3ee6a426d7ec4e289fd404948313887c rdf:first sg:person.010010511261.46
131 rdf:rest Nee50c7873f9f4bf5a3109e28c902e1e8
132 N60a5b4fb9ff44bdc82e5f8a21ed4d9d3 schema:volumeNumber 21
133 rdf:type schema:PublicationVolume
134 N69e2654b21574aeeae09465538ae63d7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Disease-Free Survival
136 rdf:type schema:DefinedTerm
137 N72084421a0b74aa28e9ce1711d7a4459 rdf:first sg:person.0711063504.30
138 rdf:rest rdf:nil
139 N76dde25a71b04f09bd3cb420d4169077 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Female
141 rdf:type schema:DefinedTerm
142 N77cfe1633f1a4f3ba0ec4bdf6f150ed1 rdf:first sg:person.01173460062.64
143 rdf:rest N7abebd083bfd4ed19ac48d7c582d3514
144 N7abebd083bfd4ed19ac48d7c582d3514 rdf:first sg:person.01366302515.33
145 rdf:rest N3ee6a426d7ec4e289fd404948313887c
146 N82a900df8f4f4fdba97800c9d2ef2b4f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Gene Expression Regulation
148 rdf:type schema:DefinedTerm
149 N84c4d4b4449f45ed942ea6fc2f4da5e2 rdf:first sg:person.01123511101.52
150 rdf:rest N72084421a0b74aa28e9ce1711d7a4459
151 N94fd1da861bd4243b6d008ae341e85dc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name YY1 Transcription Factor
153 rdf:type schema:DefinedTerm
154 N97a92abe4eb2430a85a57414d3f6bbc9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Carcinoma, Non-Small-Cell Lung
156 rdf:type schema:DefinedTerm
157 N991e5e78a52c4c6baebb53b1d969c040 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Middle Aged
159 rdf:type schema:DefinedTerm
160 Na6ddb9c31f944492ac6bdbca429057df schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Receptors, Retinoic Acid
162 rdf:type schema:DefinedTerm
163 Nbb7ca465729c42348b32b10cbd8d67b7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Diagnosis, Computer-Assisted
165 rdf:type schema:DefinedTerm
166 Nc12e95dfd85d46d3a03e375f9477f1cd schema:name doi
167 schema:value 10.1007/s10147-016-1002-0
168 rdf:type schema:PropertyValue
169 Nc608bf54d55b4bf6bb0f71aadcff197f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Prognosis
171 rdf:type schema:DefinedTerm
172 Nc6ca3df04c1d40ae987c0712eb1f7b3d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Antineoplastic Agents
174 rdf:type schema:DefinedTerm
175 Nc8fbb58c583041ef974cd8d3e7f48aad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Retinoic Acid Receptor alpha
177 rdf:type schema:DefinedTerm
178 Ncbe13d46008f40349e5e87fa37ceaf8a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Lung Neoplasms
180 rdf:type schema:DefinedTerm
181 Nda08c5885fa84af6a13153f5884d9c4c schema:issueNumber 6
182 rdf:type schema:PublicationIssue
183 Ne8d45cbede57484da7c06f46f97821b5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Immunohistochemistry
185 rdf:type schema:DefinedTerm
186 Ned80bdf564bd4af9a63ec269b8d9157b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Transcription Factors
188 rdf:type schema:DefinedTerm
189 Nee50c7873f9f4bf5a3109e28c902e1e8 rdf:first sg:person.01244323444.40
190 rdf:rest N84c4d4b4449f45ed942ea6fc2f4da5e2
191 Nf63a74bd309548fe8bab401bdff3b6d3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Aged
193 rdf:type schema:DefinedTerm
194 Nfcda6e38b69b4a32832875f81d247c69 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Cisplatin
196 rdf:type schema:DefinedTerm
197 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
198 schema:name Medical and Health Sciences
199 rdf:type schema:DefinedTerm
200 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
201 schema:name Oncology and Carcinogenesis
202 rdf:type schema:DefinedTerm
203 sg:journal.1312225 schema:issn 1341-9625
204 1437-7772
205 schema:name International Journal of Clinical Oncology
206 schema:publisher Springer Nature
207 rdf:type schema:Periodical
208 sg:person.010010511261.46 schema:affiliation grid-institutes:None
209 schema:familyName Maldonado
210 schema:givenName Altagracia
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010010511261.46
212 rdf:type schema:Person
213 sg:person.01123511101.52 schema:affiliation grid-institutes:None
214 schema:familyName Baay-Guzmán
215 schema:givenName Guillermina
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01123511101.52
217 rdf:type schema:Person
218 sg:person.01171343223.95 schema:affiliation grid-institutes:None
219 schema:familyName Huerta-Yepez
220 schema:givenName Sara
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171343223.95
222 rdf:type schema:Person
223 sg:person.01173460062.64 schema:affiliation grid-institutes:grid.419167.c
224 schema:familyName Ramírez-Tirado
225 schema:givenName Laura-Alejandra
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01173460062.64
227 rdf:type schema:Person
228 sg:person.01244323444.40 schema:affiliation grid-institutes:None
229 schema:familyName Hernández-Cueto
230 schema:givenName Daniel
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01244323444.40
232 rdf:type schema:Person
233 sg:person.01266562033.98 schema:affiliation grid-institutes:grid.419167.c
234 schema:familyName Hernández-Pedro
235 schema:givenName Norma
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01266562033.98
237 rdf:type schema:Person
238 sg:person.01335727426.76 schema:affiliation grid-institutes:grid.419167.c
239 schema:familyName Muñiz-Hernández
240 schema:givenName Saé
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01335727426.76
242 rdf:type schema:Person
243 sg:person.01366302515.33 schema:affiliation grid-institutes:grid.419167.c
244 schema:familyName Aviles-Salas
245 schema:givenName Alejandro
246 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01366302515.33
247 rdf:type schema:Person
248 sg:person.0711063504.30 schema:affiliation grid-institutes:grid.419167.c
249 schema:familyName Arrieta
250 schema:givenName Oscar
251 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0711063504.30
252 rdf:type schema:Person
253 grid-institutes:None schema:alternateName Molecular Markers Laboratory, Hospital Infantil de México “Federico Gómez”, Secretaría de Salud, Mexico City, Mexico
254 schema:name Molecular Markers Laboratory, Hospital Infantil de México “Federico Gómez”, Secretaría de Salud, Mexico City, Mexico
255 rdf:type schema:Organization
256 grid-institutes:grid.419167.c schema:alternateName Department of Pathology, Instituto Nacional de Cancerología, Mexico City, Mexico
257 Laboratory of Personalized Medicine, Instituto Nacional de Cancerología, Mexico City, Mexico
258 Thoracic Oncology Unit, Instituto Nacional de Cancerología, San Fernando # 22, Tlalpan, 14080, Mexico City, Mexico
259 schema:name Department of Pathology, Instituto Nacional de Cancerología, Mexico City, Mexico
260 Laboratory of Personalized Medicine, Instituto Nacional de Cancerología, Mexico City, Mexico
261 Thoracic Oncology Unit, Instituto Nacional de Cancerología, San Fernando # 22, Tlalpan, 14080, Mexico City, Mexico
262 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...